nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—chronic obstructive pulmonary disease	0.213	0.509	CbGaD
Dapagliflozin—CYP1A2—chronic obstructive pulmonary disease	0.205	0.491	CbGaD
Dapagliflozin—CYP2A6—Arformoterol—chronic obstructive pulmonary disease	0.0619	0.151	CbGbCtD
Dapagliflozin—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.0619	0.151	CbGbCtD
Dapagliflozin—CYP2A6—Montelukast—chronic obstructive pulmonary disease	0.0469	0.115	CbGbCtD
Dapagliflozin—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.0275	0.0673	CbGbCtD
Dapagliflozin—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0213	0.052	CbGbCtD
Dapagliflozin—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0213	0.052	CbGbCtD
Dapagliflozin—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0201	0.0491	CbGbCtD
Dapagliflozin—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0195	0.0476	CbGbCtD
Dapagliflozin—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0195	0.0476	CbGbCtD
Dapagliflozin—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0174	0.0424	CbGbCtD
Dapagliflozin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0163	0.0399	CbGbCtD
Dapagliflozin—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0161	0.0394	CbGbCtD
Dapagliflozin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.011	0.027	CbGbCtD
Dapagliflozin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0105	0.0257	CbGbCtD
Dapagliflozin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00938	0.0229	CbGbCtD
Dapagliflozin—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00919	0.0224	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00868	0.0212	CbGbCtD
Dapagliflozin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00551	0.0135	CbGbCtD
Dapagliflozin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0052	0.0127	CbGbCtD
Dapagliflozin—Diuresis—Aminophylline—chronic obstructive pulmonary disease	0.00322	0.0374	CcSEcCtD
Dapagliflozin—Venous thrombosis—Aminophylline—chronic obstructive pulmonary disease	0.00185	0.0215	CcSEcCtD
Dapagliflozin—Canagliflozin—ALB—chronic obstructive pulmonary disease	0.00163	1	CrCbGaD
Dapagliflozin—Fluid overload—Aminophylline—chronic obstructive pulmonary disease	0.00161	0.0186	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.0158	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Salbutamol—chronic obstructive pulmonary disease	0.00131	0.0152	CcSEcCtD
Dapagliflozin—Fluid overload—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.0134	CcSEcCtD
Dapagliflozin—Extravasation—Aminophylline—chronic obstructive pulmonary disease	0.00115	0.0133	CcSEcCtD
Dapagliflozin—Lung disorder—Formoterol—chronic obstructive pulmonary disease	0.00107	0.0125	CcSEcCtD
Dapagliflozin—Lung disorder—Arformoterol—chronic obstructive pulmonary disease	0.00107	0.0125	CcSEcCtD
Dapagliflozin—Lung disorder—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.0118	CcSEcCtD
Dapagliflozin—SLC5A1—respiratory system—chronic obstructive pulmonary disease	0.000972	0.205	CbGeAlD
Dapagliflozin—Influenza—Roflumilast—chronic obstructive pulmonary disease	0.00094	0.0109	CcSEcCtD
Dapagliflozin—Phlebitis—Aminophylline—chronic obstructive pulmonary disease	0.000842	0.00976	CcSEcCtD
Dapagliflozin—Infestation NOS—Roflumilast—chronic obstructive pulmonary disease	0.000839	0.00972	CcSEcCtD
Dapagliflozin—Infestation—Roflumilast—chronic obstructive pulmonary disease	0.000839	0.00972	CcSEcCtD
Dapagliflozin—Polyuria—Aminophylline—chronic obstructive pulmonary disease	0.000826	0.00958	CcSEcCtD
Dapagliflozin—Nocturia—Formoterol—chronic obstructive pulmonary disease	0.00082	0.00951	CcSEcCtD
Dapagliflozin—Nocturia—Arformoterol—chronic obstructive pulmonary disease	0.00082	0.00951	CcSEcCtD
Dapagliflozin—Urinary tract infection—Roflumilast—chronic obstructive pulmonary disease	0.000815	0.00945	CcSEcCtD
Dapagliflozin—SLC5A1—bronchus—chronic obstructive pulmonary disease	0.0008	0.169	CbGeAlD
Dapagliflozin—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.00074	0.00857	CcSEcCtD
Dapagliflozin—SLC5A1—trachea—chronic obstructive pulmonary disease	0.000718	0.152	CbGeAlD
Dapagliflozin—Neoplasm—Arformoterol—chronic obstructive pulmonary disease	0.000688	0.00797	CcSEcCtD
Dapagliflozin—Neoplasm—Formoterol—chronic obstructive pulmonary disease	0.000688	0.00797	CcSEcCtD
Dapagliflozin—Pain in extremity—Tiotropium—chronic obstructive pulmonary disease	0.000684	0.00793	CcSEcCtD
Dapagliflozin—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.000655	0.0076	CcSEcCtD
Dapagliflozin—Dehydration—Tiotropium—chronic obstructive pulmonary disease	0.000636	0.00738	CcSEcCtD
Dapagliflozin—Back pain—Roflumilast—chronic obstructive pulmonary disease	0.000634	0.00735	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Salbutamol—chronic obstructive pulmonary disease	0.0006	0.00695	CcSEcCtD
Dapagliflozin—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.000599	0.00694	CcSEcCtD
Dapagliflozin—Angina pectoris—Tiotropium—chronic obstructive pulmonary disease	0.000576	0.00668	CcSEcCtD
Dapagliflozin—Thirst—Montelukast—chronic obstructive pulmonary disease	0.000568	0.00659	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000566	0.00656	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000566	0.00656	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.000554	0.00642	CcSEcCtD
Dapagliflozin—Dysuria—Tiotropium—chronic obstructive pulmonary disease	0.000553	0.00641	CcSEcCtD
Dapagliflozin—Discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000551	0.00639	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000534	0.00619	CcSEcCtD
Dapagliflozin—Infection—Roflumilast—chronic obstructive pulmonary disease	0.000531	0.00616	CcSEcCtD
Dapagliflozin—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000519	0.00602	CcSEcCtD
Dapagliflozin—Renal failure—Tiotropium—chronic obstructive pulmonary disease	0.000518	0.00601	CcSEcCtD
Dapagliflozin—SLC5A1—lung—chronic obstructive pulmonary disease	0.000516	0.109	CbGeAlD
Dapagliflozin—Multiple fractures—Prednisone—chronic obstructive pulmonary disease	0.000515	0.00597	CcSEcCtD
Dapagliflozin—Fracture—Prednisone—chronic obstructive pulmonary disease	0.000515	0.00597	CcSEcCtD
Dapagliflozin—Dehydration—Formoterol—chronic obstructive pulmonary disease	0.000514	0.00595	CcSEcCtD
Dapagliflozin—Dehydration—Arformoterol—chronic obstructive pulmonary disease	0.000514	0.00595	CcSEcCtD
Dapagliflozin—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.000513	0.00594	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Formoterol—chronic obstructive pulmonary disease	0.000494	0.00572	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Arformoterol—chronic obstructive pulmonary disease	0.000494	0.00572	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Montelukast—chronic obstructive pulmonary disease	0.000484	0.00561	CcSEcCtD
Dapagliflozin—Influenza—Formoterol—chronic obstructive pulmonary disease	0.000477	0.00553	CcSEcCtD
Dapagliflozin—Influenza—Arformoterol—chronic obstructive pulmonary disease	0.000477	0.00553	CcSEcCtD
Dapagliflozin—UGT2B4—lung—chronic obstructive pulmonary disease	0.000476	0.1	CbGeAlD
Dapagliflozin—Influenza—Montelukast—chronic obstructive pulmonary disease	0.000468	0.00542	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.000468	0.00542	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000466	0.0054	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.000465	0.00539	CcSEcCtD
Dapagliflozin—Angina pectoris—Formoterol—chronic obstructive pulmonary disease	0.000465	0.00539	CcSEcCtD
Dapagliflozin—Angina pectoris—Arformoterol—chronic obstructive pulmonary disease	0.000465	0.00539	CcSEcCtD
Dapagliflozin—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.000464	0.00538	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000462	0.00535	CcSEcCtD
Dapagliflozin—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000457	0.0053	CcSEcCtD
Dapagliflozin—Influenza—Salbutamol—chronic obstructive pulmonary disease	0.000451	0.00522	CcSEcCtD
Dapagliflozin—Angina pectoris—Salbutamol—chronic obstructive pulmonary disease	0.000439	0.00509	CcSEcCtD
Dapagliflozin—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000425	0.00492	CcSEcCtD
Dapagliflozin—Dysuria—Salbutamol—chronic obstructive pulmonary disease	0.000421	0.00488	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Arformoterol—chronic obstructive pulmonary disease	0.00042	0.00486	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Formoterol—chronic obstructive pulmonary disease	0.00042	0.00486	CcSEcCtD
Dapagliflozin—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.000417	0.00484	CcSEcCtD
Dapagliflozin—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.000417	0.00484	CcSEcCtD
Dapagliflozin—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.000417	0.00483	CcSEcCtD
Dapagliflozin—Infestation—Montelukast—chronic obstructive pulmonary disease	0.000417	0.00483	CcSEcCtD
Dapagliflozin—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000414	0.00479	CcSEcCtD
Dapagliflozin—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000414	0.00479	CcSEcCtD
Dapagliflozin—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.000412	0.00478	CcSEcCtD
Dapagliflozin—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.000399	0.00462	CcSEcCtD
Dapagliflozin—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000394	0.00457	CcSEcCtD
Dapagliflozin—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.00453	CcSEcCtD
Dapagliflozin—Fungal infection—Prednisone—chronic obstructive pulmonary disease	0.000388	0.00449	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000377	0.00437	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000377	0.00437	CcSEcCtD
Dapagliflozin—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000377	0.00436	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00435	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00435	CcSEcCtD
Dapagliflozin—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00434	CcSEcCtD
Dapagliflozin—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00434	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00037	0.00428	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000368	0.00426	CcSEcCtD
Dapagliflozin—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000367	0.00425	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000357	0.00413	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000356	0.00413	CcSEcCtD
Dapagliflozin—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00412	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000355	0.00411	CcSEcCtD
Dapagliflozin—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000354	0.00411	CcSEcCtD
Dapagliflozin—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000354	0.0041	CcSEcCtD
Dapagliflozin—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.0041	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000348	0.00404	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.000344	0.00399	CcSEcCtD
Dapagliflozin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000337	0.00391	CcSEcCtD
Dapagliflozin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000337	0.0039	CcSEcCtD
Dapagliflozin—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000336	0.0039	CcSEcCtD
Dapagliflozin—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000335	0.00388	CcSEcCtD
Dapagliflozin—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000334	0.00387	CcSEcCtD
Dapagliflozin—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000333	0.00386	CcSEcCtD
Dapagliflozin—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000333	0.00385	CcSEcCtD
Dapagliflozin—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000333	0.00385	CcSEcCtD
Dapagliflozin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000327	0.00379	CcSEcCtD
Dapagliflozin—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000322	0.00373	CcSEcCtD
Dapagliflozin—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000322	0.00373	CcSEcCtD
Dapagliflozin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000318	0.00368	CcSEcCtD
Dapagliflozin—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000314	0.00364	CcSEcCtD
Dapagliflozin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000304	0.00352	CcSEcCtD
Dapagliflozin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000304	0.00352	CcSEcCtD
Dapagliflozin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000304	0.00352	CcSEcCtD
Dapagliflozin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000298	0.00345	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00029	0.00337	CcSEcCtD
Dapagliflozin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000288	0.00333	CcSEcCtD
Dapagliflozin—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000287	0.00333	CcSEcCtD
Dapagliflozin—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000287	0.00333	CcSEcCtD
Dapagliflozin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.00333	CcSEcCtD
Dapagliflozin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000283	0.00328	CcSEcCtD
Dapagliflozin—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000282	0.00327	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000281	0.00326	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.00326	CcSEcCtD
Dapagliflozin—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00324	CcSEcCtD
Dapagliflozin—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00324	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00319	CcSEcCtD
Dapagliflozin—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00315	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00315	CcSEcCtD
Dapagliflozin—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00315	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00315	CcSEcCtD
Dapagliflozin—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.00314	CcSEcCtD
Dapagliflozin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00313	CcSEcCtD
Dapagliflozin—Infection—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00313	CcSEcCtD
Dapagliflozin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000267	0.0031	CcSEcCtD
Dapagliflozin—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00308	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00308	CcSEcCtD
Dapagliflozin—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00306	CcSEcCtD
Dapagliflozin—Infection—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00306	CcSEcCtD
Dapagliflozin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.00306	CcSEcCtD
Dapagliflozin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000264	0.00306	CcSEcCtD
Dapagliflozin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000263	0.00305	CcSEcCtD
Dapagliflozin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000258	0.00299	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00297	CcSEcCtD
Dapagliflozin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00297	CcSEcCtD
Dapagliflozin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00295	CcSEcCtD
Dapagliflozin—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000254	0.00294	CcSEcCtD
Dapagliflozin—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000254	0.00294	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.00025	0.0029	CcSEcCtD
Dapagliflozin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000249	0.00289	CcSEcCtD
Dapagliflozin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000248	0.00287	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00287	CcSEcCtD
Dapagliflozin—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00278	CcSEcCtD
Dapagliflozin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000236	0.00273	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00272	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00272	CcSEcCtD
Dapagliflozin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.00269	CcSEcCtD
Dapagliflozin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000232	0.00269	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00266	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.00263	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000226	0.00262	CcSEcCtD
Dapagliflozin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000225	0.00261	CcSEcCtD
Dapagliflozin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000225	0.0026	CcSEcCtD
Dapagliflozin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000223	0.00259	CcSEcCtD
Dapagliflozin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000222	0.00258	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00256	CcSEcCtD
Dapagliflozin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00254	CcSEcCtD
Dapagliflozin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.0025	CcSEcCtD
Dapagliflozin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000216	0.0025	CcSEcCtD
Dapagliflozin—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00249	CcSEcCtD
Dapagliflozin—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00249	CcSEcCtD
Dapagliflozin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.00246	CcSEcCtD
Dapagliflozin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.00246	CcSEcCtD
Dapagliflozin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000212	0.00246	CcSEcCtD
Dapagliflozin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00245	CcSEcCtD
Dapagliflozin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00244	CcSEcCtD
Dapagliflozin—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00244	CcSEcCtD
Dapagliflozin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00236	CcSEcCtD
Dapagliflozin—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00235	CcSEcCtD
Dapagliflozin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.0002	0.00232	CcSEcCtD
Dapagliflozin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.0002	0.00232	CcSEcCtD
Dapagliflozin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.0002	0.00232	CcSEcCtD
Dapagliflozin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000196	0.00227	CcSEcCtD
Dapagliflozin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000189	0.00219	CcSEcCtD
Dapagliflozin—CYP2A6—lung—chronic obstructive pulmonary disease	0.000188	0.0396	CbGeAlD
Dapagliflozin—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000186	0.0392	CbGeAlD
Dapagliflozin—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000183	0.0387	CbGeAlD
Dapagliflozin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00208	CcSEcCtD
Dapagliflozin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00208	CcSEcCtD
Dapagliflozin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00204	CcSEcCtD
Dapagliflozin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00198	CcSEcCtD
Dapagliflozin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00198	CcSEcCtD
Dapagliflozin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00198	CcSEcCtD
Dapagliflozin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00198	CcSEcCtD
Dapagliflozin—Headache—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00197	CcSEcCtD
Dapagliflozin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00197	CcSEcCtD
Dapagliflozin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00196	CcSEcCtD
Dapagliflozin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000168	0.00194	CcSEcCtD
Dapagliflozin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00194	CcSEcCtD
Dapagliflozin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00193	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000165	0.00191	CcSEcCtD
Dapagliflozin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00191	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000164	0.0019	CcSEcCtD
Dapagliflozin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00187	CcSEcCtD
Dapagliflozin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00187	CcSEcCtD
Dapagliflozin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00187	CcSEcCtD
Dapagliflozin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00187	CcSEcCtD
Dapagliflozin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00186	CcSEcCtD
Dapagliflozin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000158	0.00183	CcSEcCtD
Dapagliflozin—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.0018	CcSEcCtD
Dapagliflozin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00176	CcSEcCtD
Dapagliflozin—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00176	CcSEcCtD
Dapagliflozin—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.000151	0.0318	CbGeAlD
Dapagliflozin—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000148	0.00171	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.0017	CcSEcCtD
Dapagliflozin—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.0017	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00165	CcSEcCtD
Dapagliflozin—CYP1A1—trachea—chronic obstructive pulmonary disease	0.000135	0.0286	CbGeAlD
Dapagliflozin—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000131	0.00152	CcSEcCtD
Dapagliflozin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.00012	0.00139	CcSEcCtD
Dapagliflozin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.00135	CcSEcCtD
Dapagliflozin—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00131	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000111	0.00128	CcSEcCtD
Dapagliflozin—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00128	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.00126	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00124	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00124	CcSEcCtD
Dapagliflozin—Infection—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00123	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000104	0.0012	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000103	0.0012	CcSEcCtD
Dapagliflozin—CYP1A2—lung—chronic obstructive pulmonary disease	9.86e-05	0.0208	CbGeAlD
Dapagliflozin—CYP1A1—lung—chronic obstructive pulmonary disease	9.72e-05	0.0205	CbGeAlD
Dapagliflozin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.72e-05	0.00113	CcSEcCtD
Dapagliflozin—ABCB1—respiratory system—chronic obstructive pulmonary disease	9.51e-05	0.0201	CbGeAlD
Dapagliflozin—Rash—Prednisolone—chronic obstructive pulmonary disease	9.27e-05	0.00107	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.26e-05	0.00107	CcSEcCtD
Dapagliflozin—Headache—Prednisolone—chronic obstructive pulmonary disease	9.21e-05	0.00107	CcSEcCtD
Dapagliflozin—Constipation—Prednisone—chronic obstructive pulmonary disease	9.13e-05	0.00106	CcSEcCtD
Dapagliflozin—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.73e-05	0.00101	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000984	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000979	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.87e-05	0.000912	CcSEcCtD
Dapagliflozin—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.06e-05	0.000819	CcSEcCtD
Dapagliflozin—ABCB1—trachea—chronic obstructive pulmonary disease	7.03e-05	0.0148	CbGeAlD
Dapagliflozin—Rash—Prednisone—chronic obstructive pulmonary disease	6.74e-05	0.000781	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.00078	CcSEcCtD
Dapagliflozin—Headache—Prednisone—chronic obstructive pulmonary disease	6.69e-05	0.000776	CcSEcCtD
Dapagliflozin—Nausea—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000735	CcSEcCtD
Dapagliflozin—ABCB1—lung—chronic obstructive pulmonary disease	5.05e-05	0.0107	CbGeAlD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.68e-05	0.000589	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ERBB3—chronic obstructive pulmonary disease	4.67e-05	0.000587	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ERBB3—chronic obstructive pulmonary disease	4.67e-05	0.000587	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.65e-05	0.000585	CbGpPWpGaD
Dapagliflozin—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.64e-05	0.000584	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.63e-05	0.000582	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.63e-05	0.000582	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.56e-05	0.000574	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.56e-05	0.000574	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	4.53e-05	0.00057	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.5e-05	0.000567	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.46e-05	0.000561	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.46e-05	0.000561	CbGpPWpGaD
Dapagliflozin—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	4.45e-05	0.00056	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.44e-05	0.000559	CbGpPWpGaD
Dapagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	4.42e-05	0.000556	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.42e-05	0.000556	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.38e-05	0.000551	CbGpPWpGaD
Dapagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	4.36e-05	0.000549	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—SERPINE1—chronic obstructive pulmonary disease	4.32e-05	0.000544	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GC—chronic obstructive pulmonary disease	4.3e-05	0.000541	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.28e-05	0.000539	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.25e-05	0.000535	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.25e-05	0.000535	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	4.18e-05	0.000525	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NOS3—chronic obstructive pulmonary disease	4.13e-05	0.000519	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.08e-05	0.000514	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.08e-05	0.000513	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	4.06e-05	0.000511	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.04e-05	0.000508	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.03e-05	0.000507	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.03e-05	0.000507	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.02e-05	0.000506	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.01e-05	0.000504	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.99e-05	0.000503	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.97e-05	0.0005	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.95e-05	0.000497	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	3.92e-05	0.000493	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.92e-05	0.000493	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NOS2—chronic obstructive pulmonary disease	3.89e-05	0.00049	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NOS2—chronic obstructive pulmonary disease	3.89e-05	0.00049	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.86e-05	0.000486	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.61e-05	0.000455	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.59e-05	0.000452	CbGpPWpGaD
Dapagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.58e-05	0.000451	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.57e-05	0.000449	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.56e-05	0.000448	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.52e-05	0.000443	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GC—chronic obstructive pulmonary disease	3.49e-05	0.000439	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.46e-05	0.000435	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.36e-05	0.000423	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.34e-05	0.00042	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	3.32e-05	0.000418	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	3.32e-05	0.000417	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.31e-05	0.000417	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.3e-05	0.000415	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.3e-05	0.000415	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.28e-05	0.000413	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—SERPINE1—chronic obstructive pulmonary disease	3.28e-05	0.000412	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—SERPINE1—chronic obstructive pulmonary disease	3.28e-05	0.000412	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.27e-05	0.000411	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.25e-05	0.000408	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	3.18e-05	0.000401	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.15e-05	0.000397	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NOS3—chronic obstructive pulmonary disease	3.13e-05	0.000394	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NOS3—chronic obstructive pulmonary disease	3.13e-05	0.000394	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.12e-05	0.000392	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	3.11e-05	0.000392	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APIP—chronic obstructive pulmonary disease	3.11e-05	0.000392	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.11e-05	0.000392	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.07e-05	0.000386	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	3.05e-05	0.000383	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.04e-05	0.000383	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.03e-05	0.000381	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3e-05	0.000378	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	2.99e-05	0.000376	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	2.99e-05	0.000376	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.91e-05	0.000366	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.89e-05	0.000363	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.87e-05	0.000361	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.87e-05	0.000361	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.85e-05	0.000358	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	2.84e-05	0.000358	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	2.84e-05	0.000358	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.83e-05	0.000356	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.79e-05	0.000351	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.77e-05	0.000348	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ALB—chronic obstructive pulmonary disease	2.74e-05	0.000345	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.74e-05	0.000345	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—TGFB1—chronic obstructive pulmonary disease	2.73e-05	0.000344	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	2.7e-05	0.000339	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	2.69e-05	0.000339	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—EGFR—chronic obstructive pulmonary disease	2.68e-05	0.000337	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.62e-05	0.00033	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—NOS3—chronic obstructive pulmonary disease	2.62e-05	0.00033	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.62e-05	0.00033	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.6e-05	0.000327	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.59e-05	0.000325	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.58e-05	0.000325	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.57e-05	0.000323	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	2.54e-05	0.00032	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.5e-05	0.000315	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	2.49e-05	0.000313	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	2.47e-05	0.000311	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.47e-05	0.00031	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.43e-05	0.000306	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.35e-05	0.000295	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.34e-05	0.000295	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.32e-05	0.000292	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GCLC—chronic obstructive pulmonary disease	2.32e-05	0.000292	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	2.31e-05	0.000291	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.22e-05	0.000279	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.18e-05	0.000275	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.15e-05	0.000271	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CTGF—chronic obstructive pulmonary disease	2.12e-05	0.000266	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ALB—chronic obstructive pulmonary disease	2.11e-05	0.000266	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TGFB1—chronic obstructive pulmonary disease	2.07e-05	0.00026	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TGFB1—chronic obstructive pulmonary disease	2.07e-05	0.00026	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.06e-05	0.000259	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—IL6—chronic obstructive pulmonary disease	2.06e-05	0.000259	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.04e-05	0.000257	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—chronic obstructive pulmonary disease	2.03e-05	0.000255	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—chronic obstructive pulmonary disease	2.03e-05	0.000255	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.02e-05	0.000255	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.01e-05	0.000253	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GC—chronic obstructive pulmonary disease	2e-05	0.000252	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.98e-05	0.00025	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.98e-05	0.000249	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.95e-05	0.000245	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.91e-05	0.00024	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.9e-05	0.000239	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.89e-05	0.000237	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.88e-05	0.000236	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.86e-05	0.000235	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.76e-05	0.000221	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.72e-05	0.000216	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.66e-05	0.000208	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.65e-05	0.000207	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.63e-05	0.000205	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.6e-05	0.000202	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.6e-05	0.000202	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.58e-05	0.000199	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IL6—chronic obstructive pulmonary disease	1.56e-05	0.000196	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IL6—chronic obstructive pulmonary disease	1.56e-05	0.000196	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.55e-05	0.000195	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.54e-05	0.000194	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.53e-05	0.000193	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.53e-05	0.000192	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.51e-05	0.00019	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.5e-05	0.000188	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.49e-05	0.000188	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.49e-05	0.000187	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.47e-05	0.000185	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.45e-05	0.000183	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.42e-05	0.000178	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000178	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.4e-05	0.000177	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.39e-05	0.000175	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.33e-05	0.000167	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.33e-05	0.000167	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.32e-05	0.000166	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.31e-05	0.000165	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.3e-05	0.000164	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.28e-05	0.000161	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.28e-05	0.000161	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.22e-05	0.000154	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.22e-05	0.000154	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.21e-05	0.000153	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.2e-05	0.000151	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.19e-05	0.00015	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.15e-05	0.000145	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.14e-05	0.000144	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.11e-05	0.000139	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.1e-05	0.000138	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.08e-05	0.000136	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.02e-05	0.000128	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.01e-05	0.000128	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.01e-05	0.000127	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.01e-05	0.000127	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1e-05	0.000126	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	9.88e-06	0.000124	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	9.87e-06	0.000124	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ALB—chronic obstructive pulmonary disease	9.63e-06	0.000121	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.47e-06	0.000119	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.36e-06	0.000118	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NOS3—chronic obstructive pulmonary disease	9.21e-06	0.000116	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.17e-06	0.000115	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.1e-06	0.000115	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.88e-06	0.000112	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.75e-06	0.00011	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.65e-06	0.000109	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.24e-06	0.000104	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.17e-06	0.000103	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	8.15e-06	0.000103	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	8.08e-06	0.000102	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.89e-06	9.93e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALB—chronic obstructive pulmonary disease	7.83e-06	9.85e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.67e-06	9.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.59e-06	9.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.53e-06	9.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.49e-06	9.42e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NOS3—chronic obstructive pulmonary disease	7.49e-06	9.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	7.44e-06	9.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	7.37e-06	9.28e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.27e-06	9.15e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.98e-06	8.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.98e-06	8.78e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	6.9e-06	8.69e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.85e-06	8.62e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.79e-06	8.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.44e-06	8.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	6.3e-06	7.93e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.06e-06	7.63e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	6.03e-06	7.59e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.98e-06	7.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.77e-06	7.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.71e-06	7.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.66e-06	7.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.64e-06	7.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.59e-06	7.03e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.57e-06	7.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.39e-06	6.78e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.33e-06	6.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.28e-06	6.65e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.25e-06	6.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.21e-06	6.55e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.98e-06	6.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.94e-06	6.21e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.86e-06	6.12e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.84e-06	6.09e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.77e-06	6.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	4.5e-06	5.66e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.48e-06	5.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.45e-06	5.6e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.3e-06	5.41e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.22e-06	5.31e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.74e-06	4.7e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.68e-06	4.64e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.59e-06	4.52e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.43e-06	4.32e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.43e-06	4.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.38e-06	4.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.35e-06	4.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.25e-06	4.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.24e-06	4.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.21e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.87e-06	3.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.74e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.21e-06	2.78e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.12e-06	2.66e-05	CbGpPWpGaD
